Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers...( - U.S. Data Highlights Oral Xeloda v...),Health

- U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy

in Gastroesophageal and Colorectal Cancers -

NUTLEY, N.J., Jan. 24 /PRNewswire/ -- Roche announced today that a total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been accepted for presentation at the 2008 Gastrointestinal Cancers Symposium in Orlando, Fla., from Jan. 25 to 27.

Five poster presentations based on U.S. data offer additional knowledge about Xeloda. Two of these U.S. abstracts compare the safety profile and usage patterns of therapy with oral Xeloda to that of intravenous fluorouracil (5-FU) therapy in gastroesophageal cancer. A second pair of U.S. abstracts evaluates the usage patterns and cost of Xeloda-based regimens against those of 5-FU-based regimens in colon and rectal cancer. The fifth U.S. abstract highlights preclinical efficacy and tolerability results of a novel Xeloda regimen (7/7, or 7 days on, 7 days off) using higher daily doses for the treatment of colorectal cancer.
-- Jan. 25, noon to 1 p.m., [Poster No. 72], A claims database analysis of

capecitabine treatment patterns in patients with gastroesophageal

cancer (GEC) (Presenter: Wasif Saif)

-- Jan. 25, noon to 1 p.m., [Poster No. 71], Capecitabine in patients with

gastroesophageal cancer (GEC): A claims database analysis of adverse

events (AEs) (Presenter: Wasif Saif)

-- Jan. 26, 5:30 to 6:30 p.m., [Poster No. 364], A claims database cost-

comparison analysis of capecitabine in the treatment of patients with

colon or rectal cancer (CRC) (Presenter: Edward Chu)

-- Jan. 27, 7 to 8 a.m., [Poster No. 465], Capecitabine use in patients

with colon and rectal cancer (CRC): A claims database analysis of

treatment (Presenter: Edward Chu)

-- Jan. 27, 7 to 8 a.m., [Poster No. A29], In vivo activity of traditional

vs. novel regimens of capecitabine (C) alon
'/>"/>